Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers
IVMPBPK
Sponsor study identifier
interventional
12
1 country
1
Study Start
November 2016
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2016
Actual (reported)Study Completion
January 2017
Actual (reported)The present study assesses the pharmacokinetic profile of Ivermectin (IVM) in healthy human volunteers and aims to create a physiologically-based pharmacokinetic model. Planned indication is the prevention of malaria transmission.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 2017
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 2016
Date type not reportedThis date has not been verified as actual or estimated.
November 4, 2016
Actual (reported)November 15, 2016
Actual (reported)December 2016
Actual (reported)January 2017
Actual (reported)Maximum concentration (Cmax) of ivermectin in whole blood, plasma, and capillary blood
Intermittent sampling for 72 hours after dosing
Time to maximum concentration (Tmax) of ivermectin in whole blood, plasma, and capillary blood
Intermittent sampling for 72 hours after dosing
Area under the curve (AUC) of ivermectin in whole blood, plasma, and capillary blood
Intermittent sampling for 72 hours after dosing
Occurence of adverse events
For 72 hours after dosing
Laboratory changes
For 72 hours after dosing
Changes in electrocardiogram (ECG)
For 72 hours after dosing
Single dose of ivermectin 12 mg (as 4 tablets of Stromectol (R) 3 mg) orally
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University Hospital Basel
Basel, 4031, Switzerland
Stephan Krähenbühl, MD PhD
University Hospital, Basel, Switzerland
12 participants (actual enrollment reported by the registry).
First Submitted
November 4, 2016
First Posted
November 15, 2016
Study Start
November 2016
Date type not reportedThis date has not been verified as actual or estimated.
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Contact the study team to confirm eligibility.
Primary Completion
December 2016
Actual (reported)Study Completion
January 2017
Actual (reported)Last Updated
February 1, 2017
Record last verified: 2017-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: